Select a Region North America

Insights

Insights From Our Experts

Articles

Case Study: Early-Stage Asset Valuation

The rewards of developing a new drug can be very attractive but they come with inherent risks. It is important to ensure that investment decisions on clinical development are made after examining the risk profile of…

How Artificial Intelligence Is Transforming Pharma

From drug discovery to clinical trials to commercialization, artificial intelligence (AI) and machine learning (ML) technologies are transforming the pharma and life sciences industries. Industry leaders who recognize the potential of AI and ML are now…

NORD 2020 Insights: Entering a New Era

EVERSANA was a proud sponsor of the 2020 NORD Rare Diseases & Orphan Products Breakthrough Summit to advance the dialogue on ways to improve the lives of over 25 million Americans living with rare diseases. Our…

Compliance – The Competitive Differentiator to Commercialization: An Integrated Model Setting the New Global Standard

The Compliance experts at EVERSANA prove how integrated life science compliance has earned its seat at the table by demonstrating the value of increasing data-driven and technology-infused competitiveness in the successful commercialization of a new-age biopharma…

Doing the Right Things Right: A Perspective on Rare Disease Drug Development

Millions of patients with rare diseases have benefited from the emphasis biopharmaceutical companies have put on the development of orphan drugs over the last decades. The more patients served, the more complex and challenging it becomes,…

Looking To Launch Or Commercialise In The US?

Launching a product is a serious undertaking, requiring a seamless approach to building a commercialisation strategy that includes all the variables needed to maximise the investment across the product’s lifecycle. Nowhere is this more true than…

What kind of clinical data is required for FDA clearance of a Digital Medicine?

What kind of clinical data is required for FDA clearance of a Digital Medicine? It depends. Digital therapeutics and digital medicines that are subject to FDA regulation are considered medical devices. The amount of clinical data…

Patient Recruitment & Retention: A Perspective From “The Other Side” [Webinar]

[Webinar: 23 Minutes] With over 20 years experience on the clinical research arena, Mike Ryan shares the importance of patient engagement from the clinical trial all the way across the drug development continuum. He highlights that…

Social Media for Clinical Trial Patient Recruitment: The Comprehensive Guide

A clinical trial is the sole way that new medicines come to market. Mastering the process of finding, engaging, and activating patients for enrollment into a clinical trial is a key success factor for all biopharmaceutical…

The Four Biggest Recruitment Issues for Clinical Operations Teams … And How to Solve Them.

Eighty percent of clinical trials in the United States fail to meet their patient recruitment timelines [1, 2] and 15-20% of activated clinical trial sites never enroll a single patient. [2] Meanwhile, 50% of clinical trial…